Writing the Overall Conclusion and Actions Section in a PBRER

The concluding section of a PBRER converts the completed scientific assessment into a concise statement of what has changed, what the current benefit-risk position is, and what action follows. It should not introduce a new assessment. By the time the reader reaches this section, the report should already have established the evidence, evaluated signals and risks, considered benefits and completed the integrated benefit-risk judgement.

Purpose and Regulatory Framework

The PBRER format is defined by ICH E2C(R2) and implemented for EU PSURs through Commission Implementing Regulation (EU) No 520/2012 and GVP Module VII — Periodic safety update report (Rev. 1).

The conclusions and actions section is therefore the final link in a chain:

new and cumulative evidence → signal and risk evaluation → benefit evaluation → integrated benefit-risk judgement → conclusion and action.

A conclusion that cannot be traced backwards through that chain is not adequately supported.

What This Section Should Answer

The reader should be able to determine:

• whether the overall benefit-risk balance has changed;
• which important safety conclusions changed during the interval;
• whether important uncertainty remains;
• whether existing product information and risk minimisation remain appropriate;
• whether further pharmacovigilance activity is needed; and
• which actions are completed, ongoing, proposed or subject to regulatory agreement.

The section should be concise because the reasoning has already been developed elsewhere.

Conclusion Is Not Repetition

A common weak approach is to repeat several pages of the Integrated Benefit-Risk Evaluation. The concluding section instead distils that reasoning into the decisions that matter.

For example, if a new serious risk has been identified but can be adequately managed through strengthened warnings and monitoring, the conclusion should state the updated risk status, the resulting action and why the overall balance remains favourable under the updated conditions of use. The detailed case series and causal analysis belong earlier in the report.

Distinguishing Scientific Conclusion From Regulatory Status

The MAH may reach a scientific conclusion before a competent authority has completed the corresponding regulatory procedure. The wording should therefore distinguish:

• MAH scientific conclusion — what the company considers supported by the evidence;
• action already implemented — an action that has actually taken effect;
• action agreed or required by an authority — a regulatory outcome already established;
• action proposed by the MAH — a proposal still subject to regulatory review; and
• ongoing evaluation — an issue for which no final conclusion has yet been reached.

This distinction is particularly important for product-information changes, RMP updates and additional risk-minimisation measures.

Relationship With the Integrated Benefit-Risk Evaluation

The integrated evaluation explains the reasoning. The final section states the resulting position and actions.

If the Integrated Benefit-Risk Evaluation concludes that the balance differs materially by patient subgroup, the final conclusion should preserve that distinction. A broad statement that the product remains favourable for all authorised use would otherwise erase an important scientific qualification.

Similarly, if the integrated assessment identifies unresolved uncertainty that requires additional data collection, the final section should not imply that the issue is fully resolved.

Relationship With Actions Taken for Safety Reasons

The earlier Actions Taken for Safety Reasons section records important actions implemented during the reporting interval. The final section looks forward from the current assessment.

An action already completed during the interval may be summarised as part of the final position, but it should not be presented as a new proposal. Conversely, a new action arising from the completed PBRER should be identified clearly as proposed, planned, agreed or required according to its actual status.

Turning Evidence Into Action

Actions should arise from the scientific conclusions rather than from a generic closing checklist. Depending on the evidence, appropriate consequences may include:

• no change to current pharmacovigilance or risk minimisation;
• additional routine or targeted monitoring;
• further signal evaluation;
• a proposed change to reference or local product information;
• an RMP update;
• additional pharmacovigilance activity, including a study where justified;
• modification of risk-minimisation measures;
• communication to healthcare professionals or patients; or
• a change to the authorised conditions of use, subject to the applicable regulatory procedure.

The report should not imply that every important new finding necessarily requires each of these actions.

Proportionality

The depth of the final discussion should match the significance of the conclusions. A mature product with no material change may need only a concise closing statement explaining that cumulative evidence remains consistent with the previous assessment. A report involving a new serious risk, major restriction or important change in therapeutic benefit requires a more explicit explanation of the consequences.

Conciseness is useful only when the reasoning remains intelligible.

Unchanged Benefit-Risk Is Still a Scientific Conclusion

Many PBRERs conclude that the overall benefit-risk balance remains favourable. That conclusion should not be written as a formula.

A defensible statement briefly identifies why new information does not materially alter the previous judgement. Relevant reasons may include:

• new cases remain consistent with the known risk profile;
• an important risk has been better characterised without materially increasing its clinical impact;
• negative study evidence reduces a previous uncertainty;
• new risk-minimisation controls address a newly characterised risk; or
• no important change in therapeutic benefit has occurred.

The final section should not repeat all supporting evidence, but it should make the logic visible.

When the Benefit-Risk Position Changes

A changed benefit-risk conclusion may concern the product overall or only a specific indication, dose, duration or patient population.

The author should state:

1. what changed in the evidence;
2. how that change affects the previous benefit-risk judgement;
3. which population or use is affected;
4. what action is considered necessary; and
5. the current status of that action.

This is especially important where the product remains favourable overall but additional restrictions are needed for a subgroup.

Handling Remaining Uncertainty

The conclusion should neither conceal uncertainty nor convert it into unwarranted alarm. Where evidence remains incomplete, the report should identify the uncertainty that matters to the benefit-risk balance and the mechanism by which it will be managed or reduced.

For example, an important potential risk may remain unresolved while an ongoing PASS is expected to provide more precise evidence. The appropriate conclusion may therefore be that the overall balance remains favourable, the potential risk remains under evaluation, and the planned study continues to address the residual uncertainty.

Cross-Document Consequences

A PBRER conclusion may have implications beyond the report itself. The writing team should check whether the conclusion is consistent with:

• the RMP safety specification and pharmacovigilance plan;
• reference safety information and product information;
• signal-management records;
• ongoing or planned PASS;
• risk-minimisation measures; and
• regulatory commitments.

Consistency does not mean that every document must use identical wording. Each document has a different purpose, but their scientific positions should not contradict one another without explanation.

QPPV and Governance

Organisations may define internal medical, regulatory and QPPV review arrangements for PBRER conclusions. EU pharmacovigilance requirements do not create a universal rule that the QPPV must personally author or sign every conclusion section.

The QPPV should nevertheless have appropriate oversight of significant safety conclusions, compliance issues and actions that materially affect the pharmacovigilance system or product benefit-risk profile. The mechanism by which this occurs is part of the MAH's governance design.

Illustrative Example

Consider a hypothetical medicine for a severe chronic disease. During the interval, cumulative evidence supports a new identified risk of serious infection in patients receiving concomitant high-dose immunosuppression. The risk is clinically important but appears concentrated in a recognisable subgroup, and revised monitoring and warnings are proposed.

A weak conclusion would read:

A new safety risk was identified. The benefit-risk balance remains positive and the label will be updated.

A stronger conclusion would state that cumulative evidence supports recognition of serious infection as an identified risk, particularly with concomitant high-dose immunosuppression; that the overall therapeutic benefit remains unchanged; that the benefit-risk balance remains favourable under the authorised conditions with strengthened risk communication and monitoring; and that the MAH proposes corresponding product-information and RMP updates subject to regulatory review.

Potential Writing Failure Modes

The following are illustrative writing failures, not inspection findings.

Practical Review Checklist

1. Does the section state whether the overall benefit-risk balance changed?
2. Is that statement consistent with the Integrated Benefit-Risk Evaluation?
3. Are important subgroup qualifications preserved?
4. Are major risk-status changes reflected accurately?
5. Is remaining uncertainty described proportionately?
6. Are completed actions distinguished from proposed actions?
7. Are MAH proposals distinguished from authority decisions?
8. Are resulting RMP, product-information or risk-minimisation implications clear where relevant?
9. Is every important conclusion supported earlier in the PBRER?
10. Is no new evidence introduced for the first time?
11. Is the Executive Summary consistent with the final conclusion?
12. Are actions traceable to scientific reasoning rather than a standard closing template?

Relationship With Other QPPV.com PBRER Articles

For the scientific reasoning immediately preceding this section see [[writing-the-integrated-benefit-risk-evaluation-section-in-a-pbrer]]. The opening synopsis is covered in [[writing-the-executive-summary-in-a-pbrer]]. Safety actions already implemented during the interval are discussed in [[writing-the-actions-taken-for-safety-reasons-section]]. For the whole report architecture see [[understanding-the-structure-of-a-pbrer]], [[pbrer-guide]] and [[how-to-write-a-pbrer]].

Key Takeaways

The final PBRER section states the scientific position and the actions that follow from it; it should not reopen the assessment.

A conclusion should state whether the benefit-risk balance changed and preserve important qualifications by indication, population or conditions of use.

Actions should be proportionate to the evidence and described with their true regulatory status: completed, ongoing, proposed, agreed or required.

The conclusion should reconcile with the Executive Summary, Integrated Benefit-Risk Evaluation, RMP, product information and signal records without duplicating them.

References

1. International Council for Harmonisation. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER). Step 4, 15 November 2012.
2. International Council for Harmonisation. ICH E2C(R2) Questions and Answers. Last update 31 March 2014.
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VII — Periodic safety update report (Rev. 1). EMA/816292/2011 Rev. 1.
4. European Medicines Agency. Periodic safety update reports (PSURs). Current procedural guidance.
5. European Union. Commission Implementing Regulation (EU) No 520/2012, as amended.
6. European Union. Directive 2001/83/EC, as amended.
7. European Union. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article explains authoring of the final conclusions and actions section of the PBRER/PSUR. ICH E2C(R2) and GVP Module VII define the reporting framework but do not impose a universal internal approval workflow or QPPV signature requirement for this section. As of 9 September 2026, GVP Module VII Rev. 1 remains the published EMA module; current procedural guidance should be checked for live submissions.